Kerendia (finerenone) is the first drug in its class to show a benefit ... Bayer is running an open-label study – CONFIRMATION-HF – testing Kerendia with Jardiance in patients hospitalised ...

However, amid the broader macro uncertainty, the drug and biotech sector seems to have recovered in the past month, backed by ...

Before we present a few large drug stocks that are well-positioned ... Bayer is also working to expand the labels of Nubeqa and Kerendia, which, if successful, can further drive growth.

The data will be filed with regulatory authorities to seek an expansion of the label for Nubeqa, according to Bayer, which developed Nubeqa in collaboration with Finland's Orion. The drug is ...

FDA approves updated labeling for Talzenna plus Xtandi in men with HRR gene-mutated metastatic prostate cancer, showing a ...

However, amid the broader macro uncertainty, the drug and biotech sector seems to have recovered in the past month, backed by positive pipeline and regulatory developments. Innovation is at its ...

A label begins with highlights, a succinct, half-page summary of the information that health care practitioners most commonly refer to and view as most important (Figure 2). [4] This section ...

2006 Voluntarily at any time a Includes new drug applications, biological license applications, and efficacy supplements.

Breyanzi has been approved by the FDA to treat: “With Breyanzi ... options that provide improved outcomes are available when most needed.” 3 The open-label, global, multicenter, single-arm TRANSCEND ...